Diltiazem suit
Executive Summary
Marion Merrell Dow and Rhone-Poulenc Rorer settle a suit filed by MMD alleging that RPR was inappropriately implying generic substitutability of its Dilacor XR for Cardizem CD. RPR had planned a countersuit claiming that MMD was inappropriately implying that Dilacor XR was not as bioavailable as Cardizem CD. Under terms of the agreement, announced Aug. 5, RPR has acknowledged that Dilacor XR is not generically substitutable for Cardizem CD and Marion has acknowledged that the two products "offer similar bioavailability and that both products are safe and effective antihypertensive agents".
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth